337
FIRST EXPERIENCE OF BM/PBSC-TRANSPLANTATIONS IN UKRAINE. O. Ryzhak, S. Donska, Ju. Bazaluk, N. Genkina, L. Produsevitch, N. Tretjachenko, N. Derbeniova, E. Galtchinskaja.
From June to October, 98 4 pts with Hodgkin's disease were transplanted in Pediatric Oncology-Hematology Department of Kiev Regional Oncologic Dispensary: 2 pts received ABMT and 2-combined ABMT/PBSCT. Age of patients was: 15, 18, 19 and 19 years: 2 boys and 2 girls. Indications for transplantation were: early progression after first PR (2 pts), second PR after late relapse, very early relapse after first CR. Both pts with ABMT had 4 days priming GM-CSF before BMcollection; PBSC-mobilisation was by CTX 3 g/m2+G-CSF or GM-CSF. BM-collection had 16-19 ml/kg; PBSC-collect. was made on Fresenius AS104. All pts received non-cryopreserved BM or BM/PBSC-rescue (storage +4 C 36-42 h) after Ͼ24 h of MD-CT incl. BCNU 400 mg/m2+VP-16 1 g/m2 (2 pts) or Melphalan 140 mg/m2+VP-16 1 g/m2 or BCNU 600 mg/m2. MNC-count in BM was 1.6 and 1.1 × 10/8/kg in pts with only BM-rescue but 0.7 and 0.04 × 10/8/kg in pts with BM/PBSC-rescue: number of CD34+ cells in PBSC-concentrates was 5.5 and 4.8 × 10/6/kg. All pts received G-CSF or GM-CSF during post-BMT/PBSCT period. 3 pts had engraft (Neutro Ͼ=500/mk l) on Day +23 (BMT), +18 and +19 (BM/PBSC). 1 -died before engraft (WBC 0.4 × 10/9/l) on Day +21 (pneumonia with acute respiratory distress syndrome). 1 pt had relapse 4 mths after ABMT (early progressive HD after PR; MD-CT BCNU+VP-16). 2 pts are in CR during 2.5 and 1.5 months. Our first experience showed possibility of effective noncryopreserved ABMT/PBSC-transplantation even with very limited material resources.
